Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology
January 05 2021 - 7:01AM
Business Wire
Brings More Than 30 Years of Clinical Research
and Academic Expertise in Respiratory Syncytial Virus
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced the
appointment of John P. DeVincenzo, M.D. as Vice President of
Translational Virology. In this role, Dr. DeVincenzo will provide
leadership and direction for Enanta’s pipeline of respiratory
antiviral clinical development programs and be responsible for the
strategic development and tactical implementation of the clinical
studies for these programs. Dr. DeVincenzo brings more than 30
years of clinical research and academic experience to Enanta,
predominantly focused on the pathogenesis of respiratory syncytial
virus (RSV) in children and the development of therapeutic and
prevention strategies for RSV and other respiratory viral
diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210105005335/en/
John P. DeVincenzo, M.D. (Photo: Business
Wire)
“John is a strong addition to Enanta as he has played a
significant role in nearly every RSV therapeutic advancement in the
past several decades and has worked with multiple RSV antiviral and
vaccine candidates from proof-of-concept to clinical trials,” said
Nathalie Adda, M.D., Senior Vice President and Chief Medical
Officer at Enanta. “John’s appointment to this newly-created role
reflects our commitment to advancing our RSV program and developing
treatments for other respiratory infections, such as COVID-19 and
human metapneumovirus. His specialized experience in the
development of RSV therapeutics will prove to be invaluable, and we
are thrilled to welcome him to Enanta.”
“Enanta is at the forefront of developing the leading RSV
antiviral program and I am eager to leverage my years of expertise
to help bring lifesaving therapeutics to patients in need,” stated
Dr. DeVincenzo. “I am excited by the potential of EDP-938, a
differentiated N-protein inhibitor that targets the virus’
replication machinery and has demonstrated positive Phase 2a
results in a human challenge study. With a robust clinical program
underway, including three ongoing or planned trials, I am eager to
work with the Enanta team to advance the RSV clinical program.”
Dr. DeVincenzo joins Enanta from Le Bonheur Children’s Hospital
in Memphis, Tennessee, where he was a practicing pediatric
Infectious Diseases Specialist and Medical Director of Le Bonheur's
Molecular Diagnostic and Virology Laboratories and Professor of
Pediatrics and Professor of Microbiology, Immunology, and
Biochemistry at the University of Tennessee College of Medicine.
Throughout his career, Dr. DeVincenzo has conducted numerous
clinical and translational trials refining the pathogenesis of RSV
and defining the role of prevention and therapeutic applications of
monoclonal antibodies targeting RSV in infants and the
immune-suppressed. He and his colleagues demonstrated the first
evidence that treating an established RSV infection in humans can
lower the viral load and result in reduced disease.
Dr. DeVincenzo has received numerous honors including induction
into the Alpha Omega Alpha National Medical Honor Society (2009)
and the Hero Healthcare Award for innovation (2008). He and his lab
were recognized with an Interscience Conference on Antimicrobial
Agents and Chemotherapy Program Award from the American Society for
Microbiology for best research in the area of Therapy and
Prevention of Microbial Pathogens for an abstract entitled
“Development of a Human Experimental Infection Model of Respiratory
Syncytial Virus.” He was also named as a Porter Endowed Visiting
Faculty Member at Massachusetts General Hospital, Department of
Pediatrics, as well as The Mildred and Dr. Morris Michael Endowed
Visiting Professor and Visiting Faculty Member at the National
Children’s Hospital.
Dr. DeVincenzo has a B.S. in Biology from Stanford University
and received his M.D. from Vanderbilt University School of
Medicine. He completed his residency in Pediatrics at University of
California, Los Angeles and a fellowship in Pediatric Infectious
Disease at Boston Children’s Hospital. Dr. DeVincenzo is the author
of over 250 original published abstracts and papers on the
pathogenesis of RSV in children.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections and liver
diseases. Enanta’s research and development efforts have produced
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic
steatohepatitis (NASH). Enanta is also conducting research in human
metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
FORWARD LOOKING STATEMENTS This press release contains
forward-looking statements, including statements with respect to
the prospects for advancement of Enanta’s clinical development
programs in RSV and other respiratory infections. Statements that
are not historical facts are based on management’s current
expectations, estimates, forecasts and projections about Enanta’s
business and the industry in which it operates and management’s
beliefs and assumptions. The statements contained in this release
are not guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements. Important
factors and risks that may affect actual results include: the
discovery and development risks of Enanta’s programs in RSV, hMPV
and SARS-CoV-2; the competitive impact of development, regulatory
and marketing efforts of others in those disease areas; any
continuing impact of the COVID-19 pandemic on Enanta’s business
operations and clinical trials; Enanta’s lack of clinical
development experience; Enanta’s need to attract and retain senior
management and key research and development personnel; Enanta’s
need to obtain and maintain patent protection for its product
candidates and avoid potential infringement of the intellectual
property rights of others; and other risk factors described or
referred to in “Risk Factors” in Enanta’s most recent Form 10-K for
the fiscal year ended September 30, 2020, and any other periodic
reports filed more recently with the Securities and Exchange
Commission. Enanta cautions investors not to place undue reliance
on the forward-looking statements contained in this release. These
statements speak only as of the date of this release, and Enanta
undertakes no obligation to update or revise these statements,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210105005335/en/
Investors and Media: Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024